Is Recreational Ecstasy (MDMA) Use Associated with Higher Levels of Depressive Symptoms?

Journal of Psychoactive Drugs

Volumn 39, Issue 1, 2007, Pages 31-39

  Guillot, Casey ^a  

^a UNIVERSITY OF SOUTHERN MISSISSIPPI   (United States)

Author keywords

3,4 methylenedioxymethamphetamine; 5 HT; Depression; Ecstasy; MDMA; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABIS; ILLICIT DRUG; RECREATIONAL DRUG;

ARTICLE; BECK DEPRESSION INVENTORY; DEPRESSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HAMILTON SCALE; HUMAN; MULTIPLE DRUG ABUSE; SCORING SYSTEM; SEROTONINERGIC SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOM CHECKLIST 90;

EID: 34248595492     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2007.10399862     Document Type: Article

References (77)

1. AI-Musawi A & Nu'man, M. 2001. Psychometric properties of the Beck Depression lnventory-11 with university students in Bahrain. Journal of Personality Assessment77 (3): 568-79.
2. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders.Fourth Ed. Washington, DC: American Psychiatric Association.
3. Baron, P. & Hanna, J. 1990. Egocentrism and depressive symptomatology in young adults.SocialBehavior and Personality: An International Journall8 (2): 279-85.
4. Battaglia, G.; Yeh, S.Y. & De Souza, E.B. 1988. MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons. Pharmacology Biochemistry and Behavior29 (2): 269-74.
5. Beck, A.T. & Steer, R.A. 1987. Manual for the Revised Beck Depression Inventory.San Antonio, TX: The Psychological Corporation.
6. Beck, A.T.; Steer, R.A. & Brown, G.K. 1996. Beck Depression Inventory-II Manual.San Antonio, TX: The Psychological Corporation.
7. Beck, AT.; Steer, R.A. & Garbin, M.G. 1988. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clinical Psychology Review8 (1): 77-100.
8. Beck, A.T.; Ward, CH.; Mendelson, M.; Mock, J. & Erbaugh, J. 1961.An inventory for measuring depression. Archives of General Psychiatry4 (6): 561-71.
9. Bennie, E.H.; Chakravarti, S.K.; Jarman, C.M.B.; Khan, K.; Master, D.; Murray, G.H.; Meya, U.; Soni, D.; Shaw, S.H. & White, A.C. 1988. A double-blind dose-finding study of rolipram in patients with major depressive disorder. Human Psychopharmacology: Clinical and Experimental3 (4): 275-80.
10. Buchert, R.; Thomasius, R.; Wilke, F.; Petersen, K.; Nebeling, B.; Obrocki, J.; Schulze, O.; Schmidt, U. & Clausen, M. 2004. A voxel-based PET investigation of the long-term effects of “ecstasy" consumption on brain serotonin transporters. American Journal of Psychiatry161 (7): 1181-89.
11. Buchert, R.; Thomasius, R.; Nebeling, B., Petersen, K; Obrocki, J; Jenicke, L.; Wilke, F.; Wartberg, L.; Zapletalova, P &Clausen, M. 2003. Longterm effects of “ecstasy” use on serotonin transporters of the brain investigated by PET. Journal of Nuclear Medicine 44(3): 375-84.
12. Campbell, D.B. 1996. Extrapolation from animals to man: The integration of pharmacokinetics and pharmacodynamics. Annals of the New York Academy ofSciences 80 1 (1): 116-35.
13. Cole, J.C. & Sumnall, HR. 2003. Altered states: The clinical effects of Ecstasy. Pharmacology& Therapeutics98 (1): 35-58.
14. Cole, J.C. & Sumnall, H.R. 2002. The BDI of the beholder. Journal of Psychopharmacology1 6(1): 103.
15. Commins, D.L.; Vosmer, G.; Virus, R.M.; Woolverton, W.L.; Schuster, C.R. & Seiden, L.S.1987. Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. Journal of Pharmacology and Experimental Therapeutics241 (1): 338-45.
16. Daumann, J.; Hensen, G.; Thimm, B.; Rezk, M.; Till, B. & Gouzoulis-Mayfrank, E. 2004. Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users aremainly associated with regular cannabis use: Further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacology173 (4): 398-404.
17. Daumann, J.; Pelz, S; Becker, S.; Tuchtenhagen, F. & Gouzoulis-Mayfrank, E. 2001. Psychological profile of abstinent recreational ecstasy (MDMA) users and significance of concomitant cannabis use. Human Psychopharmacology: Clinical and Experimental 16 (8): 627-33.
18. Derogatis, L.R. 1994. Symptom Checklist-90-R: Administration, Scoring and Procedures Manual.Baltimore, MD: John Hopkins University Press.
19. Derogatis, L.R.; Rickels, K. & Rock, A. 1976. The SCL-90 and the MMP1: A step in the validation of a new self-report scale. British Journal of Psychiatry128 (3): 280-89.
20. Derogatis, L.R.; Lipman, R.S. & Covi, L. 1973. An outpatient psychiatric rating scale-preliminary report. Psychopharmacology Bulletin9 (1): 13-28.
21. de Almeida, S.P & Silva, M.T.A. 2005. Characteristics of ecstasy users in Sao Paulo, Brazil. Substance Use & Misuse 40(3): 395-404.
22. de Win, M.M.L.; Reneman, L.; Reitsma, J.B.; den Heeten, G.J.; Booij, J. & van den Brink, W.2004. Mood disorders and serotonin transporter density in ecstasy users: The influence of long-term abstention, dose, and gender. Psychopharmacology173 (4): 376-82.
23. Dobson, K.S. & Breiter, H.J. 1983. Cognitive assessment of depression: Reliability and validity of three measures. Journal of Abnormal Psychology92 (1): 107-09.
24. Dozois, D.J.A. 2003. The psychometric characteristics of the Hamilton Depression Inventory. Journal of Personality Assessment80 (1): 31-40.
25. Dughiero, G.; Schifano, F. & Forza, G. 2001. Personality dimensions and psychopathological profiles of Ecstasy users. Human Psychopharmacology: Clinical and Experimental16 (8): 635-39.
26. Falck, R.S.; Carlson, R.G.; Wang, J. & Siegal, H.A. 2006. Psychiatric disorders and their correlates among young adult MDMA users in Ohio. Journal of Psychoactive Drugs38 (1): 19-29.
27. 2 l5O-positron emission tomography study. Journal of Clinical Psychopharmacology21 (1): 66-71.
28. Gerra, G.; Zaimovic, A.; Moi, G.; Giusti, F.; Gardini, S.; Delsignore, R.; Laviola, G.; Macchia, T. & Brambilla, F. 2002. Effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on dopamine system function in humans. Behavioural Brain Research134 (2): 403-410.
29. Gerra, G.; Zaimovic, A.; Ferri, M.; Zambelli, U.; Timpano, M.; Neri, E.; Marzocchi, G. F.; Delsignore, R. & Brambilla, F. 2000. Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biological Psychiatry47 (2): 127-36.
30. Gerra, G.; Zaimovic, A.; Giucastro, G.; Maestri, M; Monica, C.; Sartori. R.; Caccavari, R & Delsignore, R. 1998. Serotonergic function after (+/-)3,4-methylenedioxymethamphetamine ("ecstasy”) in humans. International Clinical Psychopharmacology13 (1): 1-9.
31. Gotlib, IH. 1984. Depression and general psychopathology in university students. Journal of Abnormal Psychology93 (I): 19-30.
32. Gouzoulis-Mayfrank, E. & Daumann, J. 2006. The confounding problem of polydrug use in recreational ecstasy/MDMA users: A brief overview. Journal of Psychophannacology20 (2): 188-93.
33. 2 receptor antagonists. European Journal of Pharmacology264 (3): 325-30.
34. Guillot, C. & Greenway, D. 2006. Recreational Ecstasy use and depression. Journal of Psychopharmacology20 (3): 411-16.
35. Halpern, J.H.; Pope, H.G.; Sherwood, A.R.; Barry, S.; Hudson, J.I. & Yougelun-Todd, D. 2004. Residual neuropsychological effects of illicit3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug andAlcohol Dependence75 (2): 135-47.
36. Hamilton, M. 1960. A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry23 (1): 56-62.
37. Hedlund, J. & Vieweg, B. 1979. The Hamilton Rating Scale for Depression: A comprehensive review. Journal of Operational Psychiatry I 0 (2): 149-62.
38. Hopkins, K.D.; Hopkins, B.R. & Glass, G.V. 1996. Basic Statisticsfor the Behavioral Sciences.Third Ed. Boston: Allyn & Bacon.
39. Huizink, A.C.; Ferdinand, R.F.; van der Ende, J. & Verhulst, F.C. 2006. Symptoms of anxiety anddepression in childhood and use of MDMA: Prospective, population based study. British Medical Journal332 (7545): 825-28.
40. Keppel, G. 1991. Design and analysis: A Researcher's Handbook Third Ed. Upper Saddle River, New Jersey: Prentice-Hall.
41. Lamers, C.T.J.; Bechara, A.; Rizzo, M. & Ramaekers, J.G. 2006. Cognitive function and mood in MD^^^TOC users, T.HC users and non-drug using controls. Journal of Psychophannacology20 (2): 302-11.
42. Leentjens, A.F.G.; Verhey, F.R.J.; Lousberg, R.; Spitsbergen, H. & Wilmink, F.W. 2002. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. InternationaiJournal ofGeriatric Psychiatry 15 (7): 644-49.
43. Lieb, R.; Schuetz, C.G.; Pfister, H.; von Sydow, K. & Wittchen, H. 2002. Mental disorders in ecstasy users: A prospective-longitudinal investigation. Drug and Alcohol Dependence68 (2): 195-207.
44. Lightfoot, S.L. & Oliver, J.M. 1985. The Beck Inventory: Psychometric properties in university students. Journal of Personality Assessment49 (4): 434-36.
45. Maclnnes, N.; Handley, S.L. & Harding, G.F.A. 2001. Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. Journal of Psychopharmacology15 (3): 181-86.
46. Maclnnes, N.; Handley, S.L. & Harding, G.F.A. 2002. The BDI of the beholder: An eye for experimental design. Journal of Psychopharmacology16 (3): 273.
47. McCann, U.D.; Szabo, Z.; Scheffel, U.; Dannals, R.F. & Ricaurte, G.A. 1998. Positron emission tomographic evidence of toxic effect of MDMA (“ecstasy”) on brain serotonin neurons in human beings. Lancet 352 (9138): 1433-37.
48. iiC]DASB. Neuropsychopharmacology30 (9): 1741-50.
49. McCardle, K.; Luebbers, S.; Carter, J.D.; Croft, R.J. & Stough, C. 2004. Chronic MDMA (ecstasy) use, cognition and mood. Psychophariacology 173 (4): 434-39.
50. Milani, R.M.; Parrott, A C.; Turner, J.J.D. & Fox, H.C. 2004. Gender differences in self-reported anxiety, depression, and somatization among ecstasy/MDMA polydrug users, alcohol/tobacco users, and nondrug users. Addictive Behaviors 29 (5): 965-71.
51. Morgan, M.J.; McFie, L.; Reetwood, L.H. & Robinson, J.A. 2002. Ecstasy (MDMA): Are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology 159 (3): 294-303.
52. Nash, J.F.; Meltzer, H.Y. & Gudelsky, G.A. 1990. Effect of 3,4-methylenedioxymethamphetamine on 3,4-dihydroxyphenylalanine accumulation in the striatum and nucleus accumbens. Journal of Neurochemistry54 (3): 1062-67.
53. O’Hearn, E.; Battaglia, G.; De Souza, E.B.; Kuhar, M.J. & Molliver, ME. 1988. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: Immunocyto-chemical evidence for neurotoxicity. Journal of Neuroscience8 (8): 2788-2803.
54. Parrott, A.C.; Sisk, E. & Turner, J.J.D. 2000. Psychobiological problems in heavy ecstasy (MDMA) polydrug users. Drug and Alcohol Dependence60 (1): 105-10.
55. Parrott, A C.; Milani, R.M.; Parmar, R. & Turner, J.J.D. 2001. Recreational ecstasy/MDMA and other drug users from the UK and Italy: Psychiatric symptoms and psychobiological problems. Psychopharmacology159 (1): 77-82.
56. Reneman, L.; Booij, J.; de Bruin, K.; Reitsma, J.B.; de Wolff, F.A.; Gunning, W.B.; den Heeten, G.J. & van den Brink, W. 200la. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358 (9296): 1864-69
57. Reneman, L.; Lavalaye, J.; Schmand, B.; de Wolff, F.A.; van den Brink, W. & den Heeten, G.J. 2001b. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or ecstasy): Preliminary findings. Archives of General Psychiatry58 (10): 901-06.
58. Ricaurte, G.A.; Martello, A.L.; Katz, J.L. & Martello, M.B. 1992. Lasting effects of (+/-)3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: Neurochemical observations. Journal of Pharmacology and Experimental Therapeutics 261 (2): 616-22.
59. Ricaurte, G.A.; DeLanney, L.E.; Irwin, I. & Langston, J.W 1988. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Research (1): 165-68.
60. Rizley, R. 1978. Depression and distortion in the attribution of causality. Journal of Abnormal Psychology 87(1): 32-48.
61. Robbins, PR. & Tanck, R.H. 1984. The Beck Depression Inventory and self-reports ofbehavior over a ten-day period. Journal of Personality Assessment48 (1): 42-45.
62. Robinson, L.A.; Berman, J.S. & Neimeyer, R.A. 1990. Psychotherapy for the treatment of depression: A comprehensive review of controlled outcome research. Psychological Bulletin108 (1): 30-49.
63. Roiser, J.P. & Sahakian, B.J. 2004. Relationship between ecstasy use and depression: A study controlling for pelydrug use. Psychopharmacology173 (4): 411-17.
64. Scanzello, C.R.; Hatzidimitriou, G.; Martello, A.L.; Katz, J.L & Ricaurte, G.A. 1993. Serotonergic recovery after (+/-)3,4-methylenedioxymethamphetamine injury: Observations in rats. Journal of Pharmacology and Experimental Therapeutics 264 (3): 1484-91.
65. Schmidt, C.J.; Abbate, G.M.; Black, C.K. & Taylor, V.L. 1990. Selective 5-hydroxytryptamine2 receptor antagonists protect against the neurotoxicity of methylenedioxymeth-amphetamine in rats. Journal of Pharmacology and Experimental Therapeutics 255 (2): 478-83.
66. Scholey, A.B.; Parrott, A.C.; Buchanan, T.; Heffernan, T.M.; Ling, J. & Rodgers, J. 2004. Increased intensity of ecstasy and polydrug usage in the more experienced recreational ecstasy/MDMA users: A study. Addictive Behaviors 29 (4): 743-52.
67. Semple, D.M.; Ebmeier, K.P; Glabus, M.F.; Carroll, R.E. & Johnstone, E C. 1999. Reducedin vivo binding to the serotonin transporter in the cerebral cortex of MDMA (ecstasy) users. British Journal of Psychiatry 175 (1): 63-69.
68. Slikker, W.; Ali, S.F.; Scallet, A.C.; Frith, C.H.; Newport, G.D. & Bailey, J.R. 1988. Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicology and Applied Pharmacology94 (3): 448-57.
69. Slikker, W.; Holson, R.R.; Ali, S.F.; Kolta, M.G.; Paule, M.G.; Scallet, A.C.; McMillan, D.E.; Bailey, J.R.; Hong, J.S. & Scalzo, F.M. 1989. Behavioral and neurochemical effects oforally administered MDMA in the rodent and nonhuman primate. NeurotoxicologylO (3): 529-42.
70. Steer, R.A. & Clark, D.A. 1997. Psychometric characteristics of the Beck Depression lnventory-11 with college students. Measurement and Evaluation in Counseling and Development 30 (3): 128-36.
71. Stone, D.M.; Hanson, G.R. & Gibb, J.W. 1987. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology 26(2): 1657-61.
72. Stone, D.M.; Merchant, K.M.; Hanson, G.R. & Gibb, J.W. 1987. Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26(12): 1677-83.
73. Storch, E.A.; Roberti, J.W. & Roth, D.A. 2004 Factor structure, concurrent validity, and internal consistency of the Beck Depression Inventory-Second Edition in a sample of college students. Depression and Anxiety 19 (3): 187-89.
74. Sumnall, H.R. & Cole, J.C. 2005. Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: A meta-analysis. Journal of Psychopharmacology19 (1): 84-92.
75. Thomasius, R.; Petersen, K.; Buchert, R.; Andresen, B.; Zapletalova, P.; Wartberg, L.; Nebeling, B. & Schmoldt, A. 2003. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology 167(1): 85-96.
76. Verkes, R.J.; Gijsman, H.J.; Pieters, M.S.M.; Schocmaker, R.C.; de Visser, S.; Kuijpers, M.; Pennings, E.J.M.; de Bruin, D; Van de Wijngaart, G; Van Gerven, J.M.A. & Cohen, A.F. 2001. Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology153 (2): 196-202.
77. Whisman, M.A. & Perez, J.E. 2005. Factor structure of the Beck Depression Inventory-Second Edition (BDI-11) in a student sample. Journal of Clinical Psychology 56 (4): 545-51.